Inventiva S.A IVA 深 沪
已收盘 08-01 16:00:00 美东时间
3.22
-0.125
-3.74%
华盛通- 最 高3.58
- 今 开3.16
- 成交量 7649股
- 最 低 3.16
- 昨 收 3.345
- 总市值 4.48亿
- 52周最高 4.05
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 1.53
- 委 比 -77.27%
- 总股本 1.39亿
- 历史最高 19.064
- 量 比 0.24
- 振 幅 12.56%
- 历史最低 1.53
- 每 手 1
- 风险率 0.52%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Inventiva Announces Preliminary First-Half 2025 Financial Results
The latest update is out from Inventiva ( ($IVA) ). On July 29, 2025, Inventiva...
07-30 05:08
Merck Receives Health Canada Approval For KEYTRUDA With Chemoradiotherapy In Stage III–IVA Cervical Cancer
Approval is based on the results from phase III KEYNOTE-A18/ENGOT-cx11/GOG-30472KIRKLAND, QC, July 21, 2025 /CNW/ -- Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced today that Health
07-21 23:01
华鑫证券-汽车行业周报：字节已产超千台物流机器人，特斯拉Q2产销量环比改善-250710
登录新浪财经APP 搜索【信披】查看更多考评等级 （转自：研报虎） ▌字节已产超千台物流机器人，关注能快速放量的重要应用场景 字节物流机...
07-10 14:55
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /PRNewswire/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the di...
07-09 20:30
Inventiva Publishes Phase 2b NATIVE Trial Data In Journal Of Hepatology Reports Showing Lanifibranor Improves Liver Cell Function In MASH And MASLD
Analysis of liver sinusoidal endothelial cells ("LSEC") from screening and end of treatment biopsies in the Phase 2b NATIVE study showed evidence of LSEC capillarization in patients without MASH, and a further increased
07-03 04:02
香港保险：为何能在全球金融波动中屹立不倒？
登录新浪财经APP 搜索【信披】查看更多考评等级 （转自：资本市场那些事儿） 前段时间，《全球金融中心指数》迎来好消息，香港总排名上升一级，位...
06-25 08:55
Inventiva S.A. reports Q1 results
Inventiva S.A. press release (OTCPK:IVEVF): Q1 As of March 31, 2025, the Company’s cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024. The decrease ...
05-23 22:32
Inventiva Reports Q1 Cash Position Of €67.9M, Eyes Funding Through Q3 2026 With Structured Financing Support
Key Financial ResultsCash, cash equivalents and depositsAs of March 31, 2025, the Company's cash and cash equivalents amounted to €67.9 million, compared to €96.6 million as of December 31, 2024.RevenuesThe Company did
05-23 15:12
Inventiva Secures €115.6 Million Through T2 Subscription Agreement
Inventiva ( ($IVA) ) has shared an update. On May 2, 2025, Inventiva S.A. enter...
05-06 05:48
Inventiva Secures €116M Second Tranche From €348M Financing To Advance Lanifibranor In MASH
Financing follows completion of enrollment of Phase 3 NATiV3 study evaluating lanifibranor in MASH and satisfaction of other specified conditions.
05-05 15:13
